Currently, CA125, expressed in the embryonic development of ovaries and re-expressed in endometriosis and ovarian neoplasms, can be used as a prognostic and predictive biomarker related to patient survival, independent of OC treatment [48]. The gene discussed is MUC16; the disease is ovarian neoplasm.